JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY临床精神药理学杂志
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY(英文缩写 J CLIN PSYCHOPHARM),ISSN 0271-0749,eISSN 1533-712X,中文译名:临床精神药理学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 3.118 | Q3 |
| 2022 | 2.900 | Q3 |
| 2023 | 2.900 | Q2 |
| 2024 | 2.800 | Q2 |
| 2025 | 2.900 | Q2 |
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY 最新收录文献
-
1. Somatic Nihilistic Delusions After Olanzapine Discontinuation in Psychotic Depression: A Case Report.
1. 精神病性抑郁中奥氮平停药后的躯体虚无妄想：一例病例报告PMID:日期:2026-10-02该文献暂无摘要。
-
2. Rapidly Enlarging Multiloculated Ovarian Cyst With Dramatic Interval Regression Following Endoxifen Discontinuation in an Adolescent Psychiatric Patient: A Probable Adverse Drug Reaction.
2. 一名青少年精神科患者停用恩多昔芬后多房性卵巢囊肿迅速增大并显著缩小：一例可能的药物不良反应PMID:日期:2026-09-23该文献暂无摘要。
-
4. Low-Dose Clozapine Versus Aripiprazole in Borderline Personality Disorder: A Prospective Naturalistic Study.
4. 低剂量氯氮平与阿立哌唑治疗边缘型人格障碍：一项前瞻性自然研究PMID:日期:2026-09-21Borderline personality disorder (BLPD) is a complex and debilitating psychiatric condition with high prevalence and clinical and psychosocial burden. Psychotherapy is the recommended first-line treatment but, in real-world clinical practice, most individuals with BLPD are prescribed psychotropic medications, including atypical antipsychotics. The literature suggests that second-generation antipsychotics may exert moderate effects on specific symptoms, but data remain limited and head-to-head comparisons are lacking. This prospective, naturalistic, follow-up study aimed to address this gap by comparing the efficacy and tolerability of low-dose clozapine versus aripiprazole in individuals with BLPD. Twenty-three patients were treated with either low-dose clozapine (n = 9) or aripiprazole (n = 14) based on clinical indication. Participants were assessed at hospital admission (T0), discharge (T1), and 3-month follow-up (T2) on emotional dysregulation, dissociative experiences, depressive symptoms, impulsivity, and quality of life. Treatment tolerability was evaluated at T1. Significant improvements in dissociation, depression, impulsivity, and quality of life were observed at both T1 and T2, independently of treatment group. Compared to aripiprazole, clozapine was associated with greater reductions in dissociative experiences at hospital discharge and in depressive symptoms at follow-up. Both treatments were safe and well tolerated. Our results suggest that low-dose clozapine is safe and may offer superior benefits for dissociative and depressive symptoms in patients with severe BLPD. Although further research is needed, these findings highlight the role of clozapine as a valuable pharmacological option in BLPD, particularly for patients with high clinical severity and inadequate response to other antipsychotics.
-
5. Successful Clozapine Rechallenge in Combination With ECT Following Paralytic Ileus: A Case Report.
5. 麻痹性肠梗阻后成功再次挑战氯氮平联合电休克治疗：一例病例报告PMID:日期:2026-09-21该文献暂无摘要。
-
6. Single-Dose Ayahuasca for Depressive and Anxiety Symptoms Associated With Cancer Diagnosis: A Single-Blind Feasibility Proof-of-Concept Trial.
6. 单剂量死藤水治疗与癌症诊断相关的抑郁和焦虑症状：一项单盲可行性概念验证试验PMID:日期:2026-09-18Depressive and anxiety symptoms are highly prevalent among patients with cancer and are associated with substantial reductions in quality of life. However, effective therapeutic options remain limited. Ayahuasca, a serotonergic psychedelic traditionally used in Amazonian ritual contexts, has shown rapid antidepressant and anxiolytic effects following a single administration in previous studies. This single-blind study included 6 female participants. Depressive and anxiety symptoms were evaluated at baseline and at 1, 2, 3 weeks and 3 months following the dosing session using the Beck Depression Inventory-II, the Patient Health Questionnaire-9 and the Beck Anxiety Inventory scales. Results indicated significant reductions in depressive and anxiety symptoms lasting up to 3 weeks following administration, with no serious adverse effects reported. Greater improvements in depressive symptoms were associated with more intense affective and subjective psychedelic experiences during the session. These preliminary findings suggest that ayahuasca may produce sustained improvements in mood and anxiety symptoms in patients with cancer. However, the small sample size and lack of a control group limit generalization, underscoring the need for larger, placebo-controlled studies.
-
7. Efficacy and Tolerability of Zonisamide for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.
7. 唑尼沙胺治疗酒精使用障碍的疗效和耐受性：一项系统综述和荟萃分析PMID:日期:2026-09-18Zonisamide, an anticonvulsant with GABAergic and glutamatergic effects, has been investigated as a treatment for alcohol use disorder (AUD), but its efficacy and tolerability remain uncertain. This systematic review and meta-analysis synthesizes evidence from randomized controlled trials evaluating zonisamide for AUD. We searched MEDLINE, Embase, PsycINFO, Scopus, and CENTRAL from inception through June 23, 2025, with an updated search on March 31, 2026, for randomized controlled trials comparing zonisamide to placebo in adults with AUD. The primary outcome was a reduction in alcohol use. Data were pooled using random-effects meta-analyses. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. Five randomized controlled trials (N=344) met inclusion criteria. Zonisamide significantly reduced drinks per day (MD=-0.79; 95% CI=-0.95 to -0.63; P<0.001) and drinking days (MD=-7.93; 95% CI=-11.03 to -4.83; P<0.001). No significant effect was observed for heavy drinking days (MD=-0.95; 95% CI=-2.12 to 0.22; P=0.11), with high heterogeneity (I²=91%). Zonisamide was associated with a significantly lower rate of nervousness, anxiety, or irritability (RR=0.53; 95% CI=0.34-0.84; P=0.007); other adverse events did not differ from placebo. Zonisamide reduced drinks per day and drinking days but not heavy drinking days, suggesting a selective benefit on overall consumption. A protective effect on nervousness, anxiety, and irritability was also observed, consistent with zonisamide's GABAergic mechanism. Further well-powered trials are needed to inform clinical recommendations.
-
9. Reply to "Clozapine-Induced Nephritis During Titrations May Be More Frequent Than What Was Described But Is Essentially Preventable".
9. 回复“滴定期间氯氮平诱导的肾炎可能比所描述的更频繁，但本质上是可预防的”PMID:日期:2026-09-18该文献暂无摘要。
-
10. Escitalopram Discontinuation-Related "Brain Zaps" in a Patient With Generalized Epilepsy.
10. 一例全面性癫痫患者中与艾司西酞普兰停药相关的“脑电击感”PMID:日期:2026-09-18该文献暂无摘要。